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The p16
INK4a protein regulates cell cycle progression mainly by inhibiting the activity of G1-phase cyclin-dependent kinases (CDKs) 4 and 6, the subsequent retinoblastoma protein (pRb) phosphorylation and E2F transcription factor release. The p16
INK4a protein can also repress the activity of other transcription factors, such as c-myc, nuclear factorkappaB and c-Jun/AP1. Here, we report that, in two p16
WT and p53 WT cell lines (MCF7 and U87), p16
INK4a overexpression induces a dramatic decrease in CDK1 protein expression. In response to p16
INK4a
, the decreased rate of CDK1 protein synthesis, its unchanged protein half-life, unreduced CDK1 mRNA steady-state levels and mRNA half-life allow us to hypothesize that p16
INK4a could regulate CDK1 expression at the post-transcriptional level. This CDK1 downregulation is mediated by the 3 0 -untranslated region (3 0 UTR) of CDK1 mRNA as shown by translational inhibition in luciferase assays and is associated with a modified expression balance of microRNAs (miRNAs) that potentially regulate CDK1, analyzed by TaqMan Human microRNA Array. The p16
-induced expression of two miRNAs (miR-410 and miR-650 chosen as an example) in MCF7 cells is confirmed by individual reverse transcriptionqPCR. Furthermore, we show the interaction of miR-410 or miR-650 with CDK1-3 0 UTR by luciferase assays. Endogenous CDK1 expression decreases upon both miRNA overexpression and increases with their simultaneous inhibition. The induction of miR-410, but not miR-650 could be related to the pRb/E2F pathway. These results demonstrate the post-transcriptional inhibition of CDK1 by p16
Introduction

The p16
INK4a protein, encoded by the INK4a gene on chromosome 9p21 (Serrano et al., 1993; Kamb et al., 1994) , is widely considered a tumor suppressor as its inactivation is frequently observed in a large variety of human malignancies (Cairns et al., 1995) , and INK4a knockout also increases cancer incidence in mice (Serrano et al., 1996) . p16
INK4a acts as a tumor suppressor through multiple biological functions, including the inhibition of cell cycle progression (Serrano et al., 1993) , the induction of senescence (Hara et al., 1996) and differentiation (Urashima et al., 1997) , and its involvement in apoptosis (Kataoka et al., 2000) and DNA repair (Shapiro et al., 1998) . The p16
INK4a protein can also impair tumor metastasis by affecting the expression of proteins involved in cell adhesion and angiogenesis (Harada et al., 1999; Nalabothula et al., 2007) . Furthermore, an emerging concept about cancer stem cells, which have self-renewal ability to perpetuate the disease, has been reported (Kopper and Hajdu, 2004; Cox et al., 2007) : the imbalance in the network, involving p16
INK4a and its transcriptional inhibitor Bmi-1, can affect stem cells self-renewal and ultimately tumor development (Molofsky et al., 2003 (Molofsky et al., , 2006 .
In the centre of these orchestrated metabolic networks, p16
INK4a has an important regulatory role in the maintenance of homeostasis. First of all, through the inhibition of the activity of cyclin-dependent kinase 4 (CDK4) and CDK6, G1-phase cell cycle kinases, p16
INK4a is involved in the transcriptional regulation of genes through CDK4/6-Rb-E2F/c-myc pathway (Serrano et al., 1993; Haas et al., 1997) . p16
INK4a also prevents transcriptional activity of nuclear factorkappaB (Wolff and Naumann, 1999) and, through JNK1/3, c-Jun/AP1 (Choi et al., 2005) , and is thought to inhibit RNA polymerase II activity by CDK7 (Nishiwaki et al., 2000) . A proteomic study has shown potential interactions of p16
INK4a with other proteins involved in the metabolism of RNA (U1 snRNP-A, snRNP-B, heterogeneous nuclear ribonucleoprotein (hnRNP) C1/C2, hnRNP A2/B1 and RuvB-like2) and of protein (HSP90, HSPA8, HS70RY, USP26 and EF-2), suggesting that p16
INK4a may regulate gene expression at other levels in addition to transcription (Souza-Rodrigues et al., 2007).
Overexpression of p16
INK4a induced the inhibition of cell proliferation, which has mainly been considered to result from arrest in G1 phase of the cell cycle (Serrano et al., 1995) . We recently reported that p16
INK4a overexpression also induces lengthening of S-phase (Chien et al., 2010) . Several reports showed reduced expression of G1-downstream cell cycle regulatory proteins, such as CDK2 and CDK1, acting in S and G2/M phases, respectively, in response to p16
INK4a overexpression (Alevizopoulos et al., 1997; Calbo et al., 2004; Chien et al., 2010) , but the mechanisms of this inhibition have not been explored until now. In the present study, using the human breast carcinoma MCF7 and the human glioblastoma U87 cell lines as models, we report that p16
INK4a overexpression downregulated CDK1 at the post-transcriptional level via the 3 0 untranslated region (UTR) of its mRNA, likely through modulation of the expression of microRNAs (miRNAs), a class of small non-coding RNAs, which are involved in post-transcriptional regulation of genes mainly by repressing mRNA translation or promoting mRNA degradation. (Lagos-Quintana et al., 2001; Hutvagner and Zamore, 2002) .
Results
p16
INK4a inhibits CDK1 expression at the post-transcriptional level To analyze the mechanism of p16-mediated CDK1 downregulation, we introduced ectopic p16
INK4a expression into MCF7 (MCF7-p16) and U87 (U87-p16) cell lines, where INK4a is deleted, but RB and p53 are wildtype. The quality of transfection was demonstrated by more than 70% of the cells expressing clearly p16
INK4a
in both cell lines, as we have previously demonstrated (Chien et al., 2010) .
The exogenous p16 INK4a protein was functional since we observed, as previously described (Chien et al., 2010) , (i) the binding of p16
INK4a to CDK4 in MCF7 (CDK6 is undetectable) by immunoprecipitation; (ii) a profound decrease in CDK4/6-mediated retinoblastoma protein (pRb) phosphorylation, demonstrated by the reduced ratio of Ser807/811-phosphorylated pRb to total pRb (decreased by 76 and 71% in MCF7-p16 and U87-p16 cells, compared with controls, respectively), whereas pRb expression itself was also decreased (Figure 1a) , as indicated by Katsuda et al. (2002) ; (iii) cell morphological changes and a reduction of alive cell number in culture (decreased by 60 and 30% in MCF7-p16 and U87-p16 cells compared with controls, respectively); and (iv) a proliferation defect confirmed by the dramatic decrease in p16
-transfected cells incorporating BrdU, compared with controls (8.7 ± 2.6 versus 23.6 ± 2.6% and 14.6±4.3 versus 31.8±5.8% in MCF7-p16 and U87-p16 cells versus controls, respectively).
In these two studied cell lines, we found that among the studied cell cycle regulatory proteins, the expression of CDK1 was the most decreased upon p16
INK4a overexpression ( Figure 1a ). Despite this protein decrease, quantitative reverse transcription-PCR (RT-qPCR) analysis using two reference genes (b-actin and 18S) and three specific primer pairs for the CDK1 gene did not reveal any variations in CDK1 mRNA expression in MCF7-p16 cells (Figure 1b and data not shown). An increased expression of CDK1 mRNA (analyzed with CDK1-a primer pair and 18S as reference gene) was observed in U87-p16 cells, compared with control cells (Figure 1c) . In contrast, the cyclin E and CDK4 mRNA levels varied in accordance with those of their proteins (Figures 1a and b) . The CDK1 mRNA half-life, analyzed by RT-qPCR, seemed to be slightly increased in MCF7-p16 cells compared with that of control cells (T 1/2 : 4.5±1.9 and 3.7±0.9 h, respectively), whereas it was clearly increased in U87-p16 cells versus controls (T 1/2 : 30.7 ± 23.8 and 3.8 ± 0.1 h, respectively) ( Figure 2a) . These results imply that the decreased CDK1 protein level may be due to decreased protein stability and/or translational inhibition.
The CDK1 protein half-life in response to p16 INK4a in MCF7 and U87 cells was then determined by cycloheximide treatment ( Figure 2b) (Figure 2c) .
To verify the specificity of the decrease in CDK1 protein translation, we analyzed the half-life of Cyclin E mRNA and protein in MCF7 cell line. We could observe a decrease in mRNA half-life after p16-overexpression (4.8±1.7 h) versus control (12.9±7.2 h). Similarly, the half-life of Cyclin E protein was slightly reduced in p16-expressing cells (34.7 ± 28.2 h) versus control (51.5 ± 14.5 h), although the expression of the protein was stronger at each time of harvesting, compared with control. Thus, it is quite unlikely that the rate of synthesis of Cyclin E protein could be reduced by p16-overexpression (Supplementary Figure 1) .
Altogether, these results indicate that CDK1 was downregulated at the post-transcriptional level upon p16
INK4a overexpression, allowing us to speculate the implication of 3 0 UTR in this regulation. To address this possibility, a luciferase reporter containing the full length CDK1-3 0 UTR (pGL3-p-CDK1-3 0 UTR, 877 bp) was generated ( Figure 3a ) and co-transfected with p16
INK4a in MCF7 and U87 cell lines. The p16
protein significantly reduced pGL3-p-CDK1-3 0 UTR reporter activity (Mann-Whitney test, Po0.05), but had no effect on the pGL3-p-cyclin E-3 0 UTR reporter (Figures 3b and c) , chosen as a control as cyclin E mRNA and protein expression did not decrease in response to p16
INK4a (Figures 1a and b, Supplementary  Figure 1 ). The extent of inhibition was around 20%, considered a significant value in studies investigating 3 0 UTR reporter activity using the luciferase reporter system (He et al., 2007; Chen et al., 2008) . Thus, miRNAs might be one possible pathway by which p16
INK4a regulates CDK1 expression. Three 3 0 -truncated CDK1-3 0 UTRs (616, 291 and 122 bp) were subsequently designed, taking into account the distribution of miRNA responsive elements (REs), predicted by miRBase or TargetScan databases (Figure 3a) . In MCF7 cells, the inhibitory effect of p16
INK4a overexpression was maintained after deleting the 616-877 CDK1-3 0 UTR sequence whereas the two other truncations (291-877 and 122-877) of the CDK1-3 0 UTR only partially rescued the inhibition (Figure 3b ). Thus, p16
INK4a could downregulate CDK1 through its 3 0 UTR and the 1-616 CDK1-3 0 UTR sequence is most important for this inhibitory effect in MCF7 cells. Together, these results suggest the possible involvement of miRNAs in CDK1 regulation in response to p16
INK4a overexpression.
A new miRNA expression balance tends to inhibit CDK1 The miRNA expression profiles were studied in MCF7-p16 and U87-p16 cells relative to control cells using the TaqMan Human MicroRNA Array in at least two independent experiments for each cell line. Among the miRNA induced or repressed in each cell line, we identified miRNAs for which putative REs were found in the CDK1-3 0 UTR sequence, identified using miRBase or TargetScan databases or miRanda software (Computational Biology Center of Memorial Sloan-kettering Cancer center, http://cbio.mskcc.org/mirnaviewer/). The assembled data showed that, in MCF7 cells, p16 (Table 1a ). In U87 cell line, p16
INK4a induced 9 miRNAs (X1.5-fold) and repressed 6 miRNAs (p0.75-fold) for which we found REs on the CDK1-3 0 UTR (Table 1b) . The miRNAs, varing upon p16
INK4a overexpression, were different between MCF7 and U87 cell lines. This might be related to the cellspecific regulation of miRNA network (Farh et al., 2005) . Further, we calculated a score to indicate potential efficacy of each miRNA on CDK1 regulation by taking into account the number of REs on the CDK1-3 0 UTR despite the influence of distance between them (Saetrom et al., 2007) , the expression level of the -induced or -repressed miRNAs, potentially active on the CDK1-3 0 UTR, were then calculated: 13.10 and -9.43, respectively, for MCF7 cell line, and 11.22 and -6.41 for U87 cell line (Table 1) . Finally, the global score, sum of the scores for induced and repressed miRNAs, was positive: 3.7 and 4.8 for MCF7 and U87 cell lines, respectively. Although rough, these positive scores allowed us to speculate that, in MCF7-p16 and U78-p16 cells, miRNAs potentially targeting CDK1 contribute to a new miRNA expression balance that tended to inhibit CDK1 expression. INK4a -induced miR-410 and miR-650 target CDK1 To verify the biological significance of these miRNA variations on the regulation of CDK1 expression, we analyzed more precisely the expression of miR-410 and miR-650 in response to p16
INK4a and their activity on CDK1 regulation in MCF7 cell line. The miR-410 and miR-650 were analyzed for several reasons: (i) although it was only weakly expressed in MCF7 cells, miR-410 was predicted by both miRBase and TargetScan databases and the sequences of its putative REs in the CDK1-3 0 UTR are conserved across three species (H. sapiens; P. troglodytes; and B. taurus), and localized within the important 1-616 region of the CDK1-3 0 UTR described above ( Figure 3a) ; (ii) miR-650 was thought to be a potential regulator of CDK1, as a threefold increase in miR-650 expression was observed in MCF7-p16 cells by TaqMan Human MicroRNA Arrays (v1.0) (Table 1a ). In addition, Although not predicted by miRbase and TargetScan databases, four putative miR-650 REs were identified in the CDK1-3 0 UTR sequence using miRanda software and two of them localized within the important 1-616 region of the CDK1-3 0 UTR (Figure 3a) .
Changes in the expression of miR-410, miR-650 and miR-16 (not predicted to target CDK1) in response to p16
INK4a were analyzed by RT-qPCR. The p16
INK4a protein significantly (Mann-Whitney test, Po0.05) induced miR-410 and miR-650 expression, whereas very slight changes in miR-16 expression were observed ( Figure 4a ). We next showed the interaction of miR-410 and miR-650 with the CDK1-3 0 UTR, as overexpression of miR-410 or miR-650 in MCF7 cells significantly (six independent experiments, Mann-Whitney test, Po0.05) inhibited pGL3-p-CDK1-3 0 UTR reporter activity (17±6 and 23±7%, respectively). The interactions between miR-410 and CDK1-3 0 UTR were direct as mutation in the seed region of both miR-410 REs abrogated the inhibition by miR-410 overexpression. Inversely, the relationships between miR-650 and CDK1-3 0 UTR appear more complex: mutation in the seed region of miR-650 REs (m1 þ 2 or m3þ 4, Figure 3a ) or the deletion of the sequence containing all the miR-650 REs (CDK1-3 0 UTR-122, Figure 3a ) did not rescue the inhibition by miR-650 overexpression ( Figure 4b) . Surprisingly, the inhibitory effect of miR-650 overexpression on CDK1-3 0 UTR was rescued when the seed region of both miR-410 REs were mutated (Figure 4b ), suggesting a cooperation between these two miRNAs, which remains to be investigated.
Further, overexpression of miR-410 or miR-650 slightly reduced endogenous CDK1 protein levels in a time-course dependent manner (28 and 37%, respectively, at 96 h) (data not shown), but did not reduce CDK1 mRNA levels, although we observed a slight decrease in CDK1 mRNA expression 72 h after miR-410 overexpression, which remains to be understood (data not shown). Successive transfections with pre-miR-650 and then pre-miR-410 led to a clear decrease (48±13%) in the CDK1 protein level at 96 h (Figure 4c ), confirming the inhibition of CDK1 by both miRNAs. The inhibition of each endogenous miRNA alone, by 2 0 -Omethyl antisense anti-miR, did not provoke any variations in CDK1 protein expression whatever the duration of the transfection changed (data not shown). However, the concomitant inhibition of miR-410 and miR-650 expression induced CDK1 protein expression (31 ± 26%) 72 h after transfection (Figure 4d) . The better results, in these gain-and loss-of-function studies, obtained with the association of both miR-410 and miR-650 argue for their cooperation in the regulation of CDK1 expression.
Role of pRb/E2F pathway in miR-410 and miR-650 regulation As some miRNA genes are reported to be regulated by E2Fs (Woods et al., 2007) , the induction of miR-410 and miR-650 expression in MCF7-p16 cells could be associated with the inhibition of the pRb/E2F pathway by p16
. Thus, we used small interfering RNA (siRNA) to knockdown the expression of E2F1 or E2F4 transcription activator or repressor, respectively (Zwicker et al., 1995; Zhu et al., 2004) . No variations in miR-650 expression were observed when E2F1 or E2F4 protein levels were sharply decreased ( Figure 5 ). In contrast, E2F4 knockdown induced miR-410 expression in a time-course dependent manner, whereas its expression was transiently reduced 48 h after addition of E2F1 siRNA ( Figure 5) .
Moreover, the human miR-410 gene is localized to the intergenic region on chromosome 14q32.31, whereas the human miR-650 gene is localized in exon 1 of the immunoglobulin-l variable gene (IGVL2-8-001). One E2F-positive RE and two E2F-negative REs (Zwicker et al., 1995; Zhu et al., 2004) were identified in the presumed core promoter region upstream of the miR-410 gene. In contrast, no E2F RE was identified within the promoter region of the miR-650 host gene (Supplementary Figure 2) .
These results suggest that p16 INK4a -induced miR-410 and miR-650 can regulate CDK1 expression and that the miR-410 gene, but not the miR-650 gene, may be upregulated through the Rb/E2F pathway in response to p16
Discussion
The major molecular function of p16 INK4a is to inhibit the activity of G1-phase kinases, CDK4 and CDK6, by which p16
INK4a prevents pRb phosphorylation and controls cell proliferation (Serrano et al., 1993) . In this study, we show that the G2/M-phases cell cycle regulatory protein, CDK1, is dramatically decreased in MCF7 and U87 cells (p16 À/À ) in response to p16
INK4a
, as previously shown with Rat-1 cells (Alevizopoulos et al., 1997) .
The significance of our findings, demonstrating the mechanism of CDK1 downregulation by p16
INK4a overexpression, is underlined by recent studies showing that CDK1 can compensate other kinase functions to maintain cell cycle progression. Indeed, according to a classic cell cycle model in higher eukaryotes, the cell cycle is governed by the successive interaction of Inhibition of CDK1 expression by p16 through miRNAs WW Chien et al different cyclin/CDK complexes. However, recent studies using gene-knockout mice have challenged certain concepts behind the cell cycle classic model and show that only CDK1 is an indispensable kinase for driving the entire cell cycle in mammals (Malumbres et al., 2004; Santamaria et al., 2007) . First, the phosphorylation of pRb by CDK4-cyclin D during the G1-phase is not necessary for its subsequent phosphorylation by CDK2-cyclin E, as the mouse embryonic fibroblasts derived from cyclin D1
À/À mice can proliferate without CDK4/6-cyclin D activity and express Thr821-phosphorylated pRb, a substrate of CDK2-cyclin E or A (Kozar et al., 2004) . In addition, CDK2 can form a complex with cyclin D and phosphorylate pRb at Ser807/811 in CDK4
mouse embryonic fibroblasts (Malumbres et al., 2004) . Second, CDK4, CDK6 and CDK2 are not essential genes for cell cycle regulation, as the disruption of each of these genes did not result in embryonic lethality, as a consequence of a critical defect in cell division. A proliferative defect was observed only in specific cell types (Berthet et al., 2003; Malumbres et al., 2004) . Third, CDK1 may compensate for CDK4, CDK6 and CDK2 as it can bind to cyclins D1, D2 and E, and phosphorylate pRb in embryonic protein extracts of CDK2
À/À mice, and ensure cell cycle progression of CDK2
À/À mouse embryonic fibroblasts in response to serum (Santamaria et al., 2007) . Finally, in contrast, the disruption of CDK1 causes an early embryonic lethality, even before morula and blastocyst stages (Santamaria et al., 2007) , indicating that CDK1 cannot be compensated for by other CDKs and is essential for cell cycle progression. Therefore, whether the compensatory mechanism is present in human MCF7 or U87 cells, INK4a overexpression, by showing the decreased rate of CDK1 protein synthesis, its unchanged protein half-life, unreduced CDK1 mRNA steady-state levels and mRNA half-life in cells expressing p16
. This post-transcriptional regulation likely involves the 3 0 UTR of CDK1 mRNA and a modified expression balance of miRNAs among which miR-410 and miR-650, induced upon p16
INK4a overexpression, regulate CDK1 expression.
The miRNA pathway is one of the mechanisms regulating gene expression at the post-transcriptional level. Localization of untranslated mRNAs to cytoplasmic processing bodies (P-bodies) is miRNA-dependent and either storage or degradation of mRNAs can occur in these structures (Liu et al., 2005; Pillai et al., 2007) . Three models were proposed for miRNA-mediated translation repression: (i) miRNAs inhibit the translation of target mRNAs per se, probably at the initiation level, leading to their subsequent sequestration to P-bodies for ultimate disposal; (ii) miRNAs provoke translocalization of target mRNAs to P-bodies and inhibit protein synthesis by preventing them from translation machinery; and (iii) miRNAs cause an initial translation repression per se, resulting in sequestration of targeted mRNAs to P-bodies reinforcing translation repression (Liu et al., 2005) . As we observed a slight (in MCF7) or clear (in U87) increase in CDK1 mRNA halflife upon p16
INK4a overexpression, storage of CDK1 mRNA in P-bodies might also be hypothesized and remains to be investigated. It should be noted that U87 cells was reported to have numerous P-bodies containing mRNA degradation or inversely RNA stabilization/ storage proteins (Moser et al., 2007) .
In p16-transfected cells, the expression of miRNAs that could potentially regulate CDK1 was stronger than in control cells, suggesting a new equilibrium of miRNA levels that tends toward inhibition of CDK1. This assumption is on the basis of the possibility that all these miRNAs together may negatively regulate CDK1 expression through its 3 0 UTR, in spite of the fact that miRNAs may induce gene expression, as recently suggested (Vasudevan et al., 2007; Eiring et al., 2010) . However, miRNA-mediated gene inhibition through 3 0 UTR is probably only one of the mechanisms regulating CDK1 in response to p16
INK4a and we cannot exclude the prospect that other post-transcriptional mechanisms through 5 0 UTR, for example, (Lytle et al., 2007) could be involved in the CDK1 inhibition in response to p16
. Furthermore, as p16
INK4a can potentially bind to hnRNP C1/C2 and hnRNP A2/B1, post-transcriptional gene regulatory factors (SouzaRodrigues et al., 2007) , and the function of hnRNPs could be disturbed through being sequestrated by certain miRNAs (Eiring et al., 2010) , it will be interesting to study the involvement of these pathways in the regulation of CDK1 expression upon p16 , miRNAs and CDK1 is illustrated by the analysis of their expressions during in vitro lymphocyte ageing (Supplementary Figure 3) . However, the negative correlation observed between the variations of the expression of p16 or miR-650 and CDK1 before and after stimulations allows us to speculate that in this model, p16
INK4a may have an important role in inhibiting cell proliferation through the induction of certain miRNAs regulating CDK1 expression.
The miRNA genes are directly regulated via their own promoters (Lagos-Quintana et al., 2001) or the promoters of their host genes (Rodriguez et al., 2004) by transcription factors, such as p53 (Raver-Shapira et al., 2007) , E2F1 (Woods et al., 2007 ), c-myc (O'Donnell et al., 2005 and JunB (Yin et al., 2008) . By inhibiting CDK4/6 activity, p16
INK4a prevents the release of E2F and c-myc from pRb and p107, respectively, and thus inhibits their transcriptional activity either for mRNA or miRNA expression. We find that E2F4 (inhibitor) knockdown induces miR-410 expression in a timedependent manner, whereas E2F1 (activator) knockdown quickly and transiently decreases miR-410 expression. Inversely, miR-650 expression does not change after knockdown of E2F1 or E2F4. As p16 INK4a overexpression leads to decreased or unchanged protein levels of E2F1 and E2F4, respectively, the induction of miR-410 expression that occurs in response to p16 INK4a could be a consequence of the reduction in the activator E2F1 expression and the decreased release of the inhibitor E2F4 from hypophosphorylated pRb family proteins. These results are consistent with the positive and negative E2F REs found in putative miR-410 promoter, but not in miR-650 promoter and suggest the involvement of other factors, which remain to be explored.
Taking together, the post-transcriptional downregulation of CDK1 expression through miRNA pathway that we demonstrated should be considered to have an important role in the p16
-induced growth inhibition. We anticipate that p16
INK4a can regulate gene expression at different levels by modifying the functional equilibrium of transcription factors and consequently of miRNAs, and by potentially binding to post-transcriptional regulators (Figure 6 ), explaining the wide and rapid consequences of its overexpression and yielding new insights into its tumor suppressor role.
Materials and methods
Cell culture and plasmids
The MCF7 (ATCC, HTB-22) and U87 cell lines were cultured in Dulbecco's modified Eagle's medium medium (4.5 and 1 g/l of glucose , respectively) (Invitrogen,Carlsbad, CA, USA), supplemented with 10% fetal calf serum (FBS), 2 mM l-Glutamine, 100 units penicillin and 100 mg streptomycin at 37 1C in a humidified atmosphere of 5% CO2.
The plasmid pcDNA3. 0 (the sequence of the XbaI restriction site is underlined). The PCR product was cut with XbaI and cloned into the XbaI site of the luciferase reporter plasmid pGL3-promoter (Promega, Charbonnieres, France).
The luciferase reporters pGL3-p-CDK1-3 0 UTR containing mutated miR-410 or miR-650 RE(s) were generated by PCR using the QuickChange site-directed mutagenesis kit (Agilent Technologies, Santa Clara, CA, USA) with the pGL3-p-CDK1- 3 
Transfections
The p16
INK4a protein was expressed in MCF7 and U87 cells after transfection of pcDNA3.1-p16 or control plasmid using Lipofectin or Lipofectamine2000, respectively (Invitrogen), Cells were plated at 0.4 Â 10 6 cells/well in six-well plates, and cultured overnight before transfection. Transfection was performed with the cells at B60-70% confluence. At 48 h after transfection, a selection was performed with geneticin G418 (Invitrogen) for 72 h. Alive cells were then harvested after removing dead cells by rinsing with phosphate-buffered saline. For all the samples, the percentage of apoptotic cells in the sub-G1 peak, analyzed by flow cytometry DNA content analysis (Supplementary information), was lower than 10%. Transfection efficiency was verified by immunocytochemistry and western blot.
The miRNA overexpression study was performed, using Lipofectamine2000, by transfecting MCF7 cells with 30 nM pre-miR-410, pre-miR-650, or pre-miR control oligonucleotides (Applied Biosystems, Carlsbad, CA, USA), twice with 24 h interval, for 48, 72 and 96 h. A double transfection was performed first with pre-miR-650 and, 48 h after, with premiR-410 for 72 and 96 h. Inhibition of endogenous miRNAs was performed, using Lipofectamine2000, by transfecting MCF7 cells with 100nM 2 0 -O-methyl antisense anti-miR-410, anti-miR-650 and anti-miR-410 plus anti-miR-650 oligonucleotides or negative control inhibitor (Applied Biosystems), twice, with 24 h interval, for 48 and 72 h. Variations of miRNAs were controlled by RT-qPCR (Supplementary Figure 4) .
For luciferase reporter assays, MCF7 cells were transfected, using Lipofectamine2000, with 1.37 mg of pcDNA3.1-p16 or pcDNA3.1, 0.25 mg of pRL-TK (Promega) and 7 mg of pGL3-p constructs containing CDK1-3 0 UTR or pGL3-p. For U87 cells, 3 mg of pcDNA3.1-p16 or pcDNA3.1 was used. Luciferase activities were analyzed 48 h after selection. The miRNA-overexpression effects on CDK1-3 0 UTR were analyzed by co-transfection of 30 nM pre-miR-410, pre-miR-650 or control pre-miR oligonucleotides with 400 ng of pGL3-p-CDK1-3 0 UTR, pGL3-p-CDK1-3 0 UTR constructs containing mutation in miR-410 or miR-650 REs or pGL3-p and 50 ng of pRL-TK. Luciferase activities were analyzed 48 h after transfection. All experiments were performed twice in triplicate. Luciferase assays were performed with the DualLuciferase reporter Assay System (Promega, Madison, WI, USA), according to manufacturer's instructions. The measures were obtained with a Luminoskan Ascent microplate luminometer (Thermo Scientific, Hudson, NH, USA). For each sample, the firefly luciferase activity was normalized with the Renilla luciferase activity, used as a control to standardize the transfection efficiency, and data obtained were normalized to that with pGL3-p control.
For siRNA study, cells were transfected, twice with 24 h interval, with 100 nM ON-TARGETplus E2F1 or E2F4 siRNAs using Lipofectamine2000, and harvested 48, 72, and 96 h after the first transfection. The siRNA target sequences were: E2F1: 5 0 -UCGGAGAACUUUCAGAUCU-3 0 (Dharmacon, Lausanne, Swizerland, J-003259-09); E2F4: 5 0 -CGGG AGACCACGAUUAUAU-3 0 (Dharmacon, J-003262-10). GL3 siRNA sequences (Dharmacon, D-001400-01) were used as a negative control. E2F1 or E2F4 protein expression was verified by western blot.
Western blot
Western blot was carried out as previously described (Baghdassarian et al., 1999) . The primary antibodies were: mouse monoclonal anti-p16
INK4a (BD PharMingen, San Diego, CA, USA), anti-pRb, anti-p107, anti-E2F1, anti-CDK1, anti-CDK7, anti-cyclin B1, anti-cyclin E, anti-p53 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and anti-b-actin antibody (Sigma, Saint Quentin Fallavier, France), rabbit polyclonal anti-Ser807/Ser811-phosphorylated pRb (Cell Signaling technology, Danvers, CA, USA), anti-E2F4, anti-CDK2, anti-CDK4, anti-CDK6, anti-cyclin A, anti-p21 CIP1 and anti-p27 KIP1 (Santa Cruz Biotechnology). Loading equality was assessed by Ponceau red staining analysis and quantification of b-actin or a non-specific protein band (Wang et al., 2005; Kaddar et al., 2009) . Quantifications were carried out by densitometric analysis using Kodak 1D Image Analysis Software (Sigma) as previously described (Baghdassarian et al., 1998) .
RT-qPCR
Total RNA was isolated using Trizol reagent according to the manufacturer's instructions (Invitrogen). The concentration and purity of the samples were assessed using a NanoDrop ND-1000 spectrophotometer (Thermo Scientific). The cDNA was synthesized by M-MLV reverse transcriptase (Invitrogen) using oligo (dT)15 (Invitrogen) as a primer. PCR reaction mixtures were made in a total volume of 6.67 ml containing 1.67 ml of diluted cDNA, 0.67 ml of LightCycler FastStart enzyme/buffer mix (Roche Diagnostics Inc., USA), 0.17 ml of each strand of specific primers (37 mM) and 3mM MgCl 2 . Quantitative PCR was performed with the LightCycler 1. 0 ; 18S (Applied Biosystems, Warrington, UK). Quantifications were performed using the Analysis-RelQuant software (Roche Diagnostics) for at least three independent experiments. Results were normalized to the reference gene b-actin or 18 S. mRNA half-life study Transfected cells were treated with 10 mg/ml of actinomycin D (Sigma) 48 h after antibiotic treatment. To estimate CDK1 mRNA half-life by RT-qPCR, CDK1-a primers were used to amplify 252 bp of the 5 0 -terminus of CDK1 cDNA (from the beginning of exon 1 to exon 3). As the cDNA was reverse transcribed using primer oligo(dT), which anneals to the 3 0 poly A tail of mRNA to guide reverse transcriptase to synthesize the entire cDNA, amplification of a fragment at the 5 0 terminus can represent detection of nearly the entire mRNA, as recommended by Leclerc et al (2002) . Results were normalized to reference gene 18S. The half-life of CDK1 mRNA was calculated according to the formula T 1/2 ¼ 0.3t/log(D1/D2), where D1 and D2 correspond to the mRNA levels at two different times and t is the corresponding interval of time. The same methodology was used to estimate cyclin E mRNA half-life.
Protein half-life and rate of protein synthesis To study the level of action of p16
INK4a on CDK1 expression, we analyzed the stability of CDK1 protein in MCF7 and U87 cells, expressing or not p16
INK4a
, after cycloheximide treatment.
